Stockreport

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 [Yahoo! Finance]

Vanda Pharmaceuticals Inc.  (VNDA) 
Last vanda pharmaceuticals inc. earnings: 2/25 04:01 pm Check Earnings Report
PDF company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of rosnilimab, a pathogenic T cell depleter, [Read more]